Tandem (TNDM) Insider Report: Morrison RSUs Vest, Tax Withholding Executed
Rhea-AI Filing Summary
Susan M. Morrison, EVP & Chief Administrative Officer of Tandem Diabetes Care, Inc. (TNDM), reported equity transactions dated 08/15/2025 on Form 4. The filing shows vesting of restricted stock units (RSUs) awarded under the 2023 Long-Term Incentive Plan: 1,503 RSUs and 1,097 RSUs were settled (transaction code M) with an acquisition price of $0 for each award. To satisfy tax withholding on the vesting, the company withheld 430 and 314 shares respectively at a withholding price of $10.82 per share; the filer states explicitly that no shares were sold. The Form indicates the transactions were reported by an attorney-in-fact on 08/19/2025. The filing itemizes the share movements and confirms the RSU grant and vesting schedule terms referenced in the explanation section of the Form.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine RSU vesting with withholding for taxes; no sales reported, minimal near-term market impact.
The Form 4 documents standard compensation settlement activity: two RSU tranches vested resulting in 1,503 and 1,097 shares acquired at $0, with 430 and 314 shares withheld to satisfy tax obligations at $10.82 per share.
This activity represents executive compensation realization rather than open-market disposition, and the filer states that no shares were sold, limiting immediate dilution or market selling pressure. The transactions are consistent with the company’s disclosed LTIP vesting schedule and thus are routine from a financial reporting perspective.
TL;DR: Governance-standard execution of equity compensation; withholding used for tax compliance, substitutions align with plan terms.
The filing cites RSUs awarded under the 2023 Long-Term Incentive Plan and explains vesting timing and settlement mechanics. Withholding of 430 and 314 shares for tax purposes is explicitly disclosed and the filer affirms no open-market sales occurred. The Form appears complete for the reported transactions and includes a signed attorney-in-fact filing, which satisfies procedural requirements for Section 16 reporting.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 1,503 | $0.00 | -- |
| Exercise | Restricted Stock Unit | 1,097 | $0.00 | -- |
| Exercise | Common Stock | 1,503 | $0.00 | -- |
| Tax Withholding | Common Stock | 430 | $10.82 | $5K |
| Exercise | Common Stock | 1,097 | $0.00 | -- |
| Tax Withholding | Common Stock | 314 | $10.82 | $3K |
Footnotes (1)
- Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan (the 2023 Plan). Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Awarded on May 23, 2024 pursuant to the 2023 Plan. RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.
